WARPTECHNEWS · LAB

Home AI Business Tech Archive

Storia: Pfizer, Innovent strike $10B cancer drug deal — Warptech Lab News

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 12 fonti

Pfizer, Innovent strike $10B cancer drug deal

Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.

Raccontata da

morningstar.com

biopharmadive.com

thehindubusinessline.com

asia.nikkei.com

pharmaceutical-technology.com

fiercepharma.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo3 mesi fa

Pfizer, Innovent strike $10B cancer drug deal

Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.

Timeline cronologica

venerdì 29 maggio 2026·morningstar.com
Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
venerdì 29 maggio 2026·morningstar.com
Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

thehindubusinessline.com

3 mesi fa

Pfizer inks up to $10.5 billion deal with China’s Innovent Biologics

Pfizer Inc. and China’s Innovent Biologics Inc. signed a global agreement worth as much as $10.5 billion to develop cancer drugs.

Leggi questa versione → originale

scmp.com3 mesi fa

China’s Innovent Biologics signs US$10.5b Pfizer deal for 12 cancer drug trials

The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer.

Leggi questa versione → originale

qz.com3 mesi fa

Pfizer and Innovent Biologics sign $10.5B cancer drug deal

The U.S. pharma giant will pay $650 million upfront to China's Innovent Biologics to co-develop 12 early-stage oncology programs

Leggi questa versione → originale

pharmaceutical-technology.com3 mesi fa

Pfizer, Innovent Biologics sign $10.5bn cancer drug development deal

Pfizer and Innovent Biologics have signed a global licensing and collaboration agreement worth up to $10.5bn for the research and development of a portfolio of 12 early-stage cancer medicines.

Leggi questa versione → originale

endpoints.news3 mesi fa

Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programs

On the eve of this year’s ASCO annual meeting, Pfizer said it is teaming up with China’s Innovent Biologics to advance a portfolio of 12 early-stage antibody-drug conjugates and multi-specific antibodies in a deal that…

Leggi questa versione → originale

venerdì 29 maggio 2026·

biopharmadive.com

Pfizer, Innovent strike $10B cancer drug deal

Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.

venerdì 29 maggio 2026·

thehindubusinessline.com

Pfizer inks up to $10.5 billion deal with China’s Innovent Biologics

Pfizer Inc. and China’s Innovent Biologics Inc. signed a global agreement worth as much as $10.5 billion to develop cancer drugs.

venerdì 29 maggio 2026·

asia.nikkei.com

China's Innovent Biologics signs drug deal with Pfizer worth up to $10.5bn

Biotech firm says global expansion still under development

venerdì 29 maggio 2026·

cnbc.com

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines.

venerdì 29 maggio 2026·

scmp.com

China’s Innovent Biologics signs US$10.5b Pfizer deal for 12 cancer drug trials

The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer.

venerdì 29 maggio 2026·

benzinga.com

Pfizer Strikes Up To $10.5 Billion Deal With Innovent Biologics - Pfizer (NYSE:PFE)

Pfizer and Innovent Biologics sign a $10.5 billion cancer drug deal to develop 12 oncology programs globally.

venerdì 29 maggio 2026·

pharmaceutical-technology.com

Pfizer, Innovent Biologics sign $10.5bn cancer drug development deal

Pfizer and Innovent Biologics have signed a global licensing and collaboration agreement worth up to $10.5bn for the research and development of a portfolio of 12 early-stage…

venerdì 29 maggio 2026·

startmag.it

L'accordo con Innovent Biologics fa tenere a Pfizer un piede negli Usa e l'altro in Cina - Startmag

La collaborazione tra Pfizer e Innovent riguarda un portafoglio di 12 programmi oncologici, composto da 8 asset in fase iniziale

venerdì 29 maggio 2026·

endpoints.news

Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programs

On the eve of this year’s ASCO annual meeting, Pfizer said it is teaming up with China’s Innovent Biologics to advance a portfolio of 12 early-stage antibody-drug conjugates and…

venerdì 29 maggio 2026·

qz.com

Pfizer and Innovent Biologics sign $10.5B cancer drug deal

The U.S. pharma giant will pay $650 million upfront to China's Innovent Biologics to co-develop 12 early-stage oncology programs

venerdì 29 maggio 2026·

fiercepharma.com

Fierce Pharma Asia—More China biotech hawkishness; Pfizer’s $10B Innovent deal; Astellas’ roadmap

As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to cur | As China-developed assets gain more attention from biopharma…